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INTRODUCTION
A genetic instability is believed to underlie the various
genomic changes in a malignancy (1). In solid tumors, uni-
lateral chromosomal losses are the most common genetic
events that are detected as a loss of heterozygosity (LOH)
using highly polymorphic microsatellite markers (2). The
extent of the unilateral chromosomal losses and the microsatel-
lite instability (MSI) detected in stage II and III gastrointesti-
nal carcinomas (3, 4) have been classified into high-level LOH
(LOH-H) and baseline-level LOH (LOH-B) in those with a
poor prognosis and low-level LOH (LOH-L) and MSI in those
with a low risk. Gastric carcinomas frequently display an
intratumoral heterogeneity with the different histological
types and varying degrees of differentiation (5, 6). Previous
multifocal LOH studies on gastric carcinomas (7, 8) report-
ed the extent of the chromosomal losses as a stem-line geno-
type commonly shared by heterogeneous tumor sites. This
suggests that the level of chromosomal losses plays a master
role in the diverse progression of gastric carcinomas.
Chromosomal losses detected by LOH analysis, in a naive
sense, represent an imbalanced loss or a dose reduction of the
genetic elements. A difference in the dose of the X chromo-
some between males (XY) and females (XX) is equalized via
a dosage compensation mechanism, which randomly inacti-
vates one of two X chromosomes via DNA hypermethylation
(9). The X-to-autosomal chromosome ratio is believed to
inherently initiate the methylation changes in order to main-
tain the genomic dosage in mammals (10, 11). Although
solid tumors suffer from global DNA hypomethylation and
multiple gene-specific hypermethylation (12), the link bet-
ween the unilateral chromosomal losses and DNA methyla-
tion is poorly understood in terms of the genetic and epige-
netic interaction including the compensative methylation
changes in response to a genome dosage reduction. There-
fore, it is important to determine if the extent of the chro-
mosomal losses is related to the pattern of DNA methyla-
tion changes.
Hypomethylation and hypermethylation involve the dif-
ferent spectra of cancers in distinct fashions. The genomic
and gene-specific hypomethylation closely correlate with
advanced-stage cancers (13, 14). Meanwhile, gene-specific
hypermethylations are widely detected in different subsets
of gastrointestinal cancers with and without MSI (15, 16).
At the genomic level, global hypomethylation of the cancer
genome is only an insignificant change affecting a small por-
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Relationship Between the Extent of Chromosomal Losses and the
Pattern of CpG Methylation in Gastric Carcinomas
The extent of unilateral chromosomal losses and the presence of microsatellite insta-
bility (MSI) have been classified into high-risk (high- and baseline-level loss) and
low-risk (low-level loss and MSI) stem-line genotypes in gastric carcinomas. A uni-
lateral genome-dosage reduction might stimulate compensation mechanism, which
maintains the genomic dosage via CpG hypomethylation. A total of 120 tumor sites
from 40 gastric carcinomas were examined by chromosomal loss analysis using
40 microsatellite markers on 8 chromosomes and methylation analysis in the 13
CpG (island/non-island) regions near the 10 genes using the bisulfite-modified DNAs.
The high-level-loss tumor (four or more losses) showed a tendency toward unmethy-
lation in the Maspin, CAGE, MAGE-A2 and RABGEF1 genes, and the other micro-
satellite-genotype (three or fewer losses and MSI) toward methylation in the p16,
hMLH1, RASSF1A, and Cyclin D2 genes (p<0.05). The non-island CpGs of the
p16 and hMLH1 genes were hypomethylated in the high-level-loss and hyperme-
thylated in the non-high-level-loss sites (p<0.05). Consequently, hypomethylation
changes were related to a high-level loss, whereas the hypermethylation changes
were accompanied by a baseline-level loss, a low-level loss, or a MSI. This indicates
that hypomethylation compensates the chromosomal losses in the process of tumor
progression.
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tion of the non-coding genetic elements in the gene- and GC-
poor heterochromatin region (14, 17). However, GC-rich
regions adjacent to the coding genes frequently exhibit hyper-
methylation in the undermethylated CpG islands (15) and
hypomethylation in the overmethylated non-island CpGs
(13), suggesting a methylation variation that is prone to
hyper- and hypomethylation changes in cancer cells. There-
fore, it is likely that both hypermethylation and hypomethy-
lation, each of which plays a distinct role in diverse tumor
progression, can be detected in the methylation variation
regions adjacent to the genes.
In this study, multifocal analysis on gastric carcinomas was
carried out to determine the relationship between the stem-
line extent of the chromosomal losses and the CpG methyla-
tion status in heterogeneous tumor tissues. A total of 120
tumor foci from 40 gastric carcinomas were examined to deter-
mine the extent of chromosomal losses using a PCR-based
LOH analysis on 8 cancer-associated chromosomal arms. The
13 extragenic regions adjacent to the 10 cancer-related or
-unrelated genes were evaluated for the methylation status
of the CpG islands and/or the non-island CpGs using methy-
lation-specific PCR (MSP) and bisulfite sequencing analyses.
The proportion of methylation and unmethylation was com-
pared to determine the rise and fall in the methylation den-
sity in the paired normal and tumor tissues.
MATERIALS AND METHODS
Patients and tumor tissues
The gastric carcinoma tissues were selected from those that
had been recently resected in a similar period because forma-
lin-fixed paraffin-embedded tissue DNA tends to be poorly
amplified by PCR in the older archives. Fifty patients who
were suspected of having a gastric carcinoma were underwent
a surgical resection at the St. Paul’s Hospital, The Catholic
University of Korea between March and December 2002.
Of the 50 patients, 40 patients, who were suitable for isolat-
ing the matching normal and tumor DNAs from the paraf-
fin-embedded tissues, and for providing the clinicopathologi-
cal information, were enrolled in this study. The normal lymph
nodes were also collected as the control. The nontumoral gas-
tric mucosa was examined for the presence or absence of intesti-
nal metaplasia. The histological type of the gastric carcinoma
was classified into intestinal, diffuse, and mixed according
to the Lauren classification (18) and the degree of differenti-
ation was graded according to the WHO classification. The
clinicopathological tumor stage was determined using the
Tumor-Node-Metastasis (TNM) criteria (19). Permission for
this study was obtained from the Institutional Review Board
and written informed consent was obtained from each patient
prior to the surgical resection.
Three tumor sites per gastric carcinoma were selected from
the topographically opposite and histologically distinct areas.
A tissue area ranging from 5 mm to 7 mm in diameter was
microdissected from an average of 10 consecutive seven- m-
thick hematoxylin-eosin-stained sections using a stereomi-
croscope under a ×40 magnification. All the microdissected
tumor sites were checked for the tumor cell contents ≥70%
prior to DNA extraction. A tumor cell content of 80-89%
held a major fraction (74 sites, 62%) of the microdissected
tissue sites followed by ≥90% (29 sites, 24%) and 70-79%
(17 sites, 14%) of the tumor cell contents. Approximately
50 microdissected cells were digested in 1  L of a Tween 20-
Proteinase K lysis buffer. An average of 100  L of the tissue
lysate from each microdissected site was examined for its LOH
status, and an average of 500  L of the lysate was subjected
to bisulfite modification to determined the methylation status
(Fig. 1). Because the digested tissue admixture contained
genomic DNA of heterogeneous quality in different concen-
tration, the amount of template DNA used for the PCR-based
microsatellite and methylation analyses was determined based
on the PCR band intensity of 20 ng/ L amplified by a micro-
satellite primer set, D19S226 (forward, 5′ -CCA GCA GAT
TTT GGT GTT GTC TA-3′ ; reverse, 5′ -ACA GAG CCA
GAG CCA GTA GGA GT-3′ ; amplicon size, 164 bp).
Microsatellite analysis
PCR amplification of the template DNA was performed
under the so-called ‘‘multiplex, hot-start’’ condition using a
radioisotope ( -32P dCTP, PerkinElmer, Boston, MA, U.S.A.)
as described previously (7, 8). For each PCR, two pairs of
microsatellite primers were used, and the template-primer
mixtures were heated prior to adding the dNTP and Taq
DNA polymerase (Takara, Shiga, Japan). One  L of the tem-
plate DNA was amplified and labeled through 32 PCR cycles
using a thermocycler (iCycler, Bio-Rad, Hercules, CA, U.S.A.)
as follows: 1 min of denaturation at 94℃, 1 min of anneal-
ing at 58-64℃, and 1 min of elongation at 72℃ in a 10  L
reaction mixture. Of the PCR products, 5  L was loaded
directly onto a sequencing gel containing 7 M urea and visu-
alized by repeated autoradiography using a radioluminograph
scanner (BAS 2500, Fuji Photo Film, Kanakawa, Japan). The
optimal range of the band intensities was measured by den-
sitometry using TINA image software (Raytest Isotopen-
me gerate GmbH, Straubenhardt, Germany). Each reaction
was repeated twice and the same band intensity was confirmed.
The MSI and LOH status were defined using a panel of 40
microsatellite markers that were selected from eight chromo-
somes, including 3p, 4p, 5q, 8p, 9p, 13q, 17p, and 18q, as
described previously (Fig. 1A) (7, 8). The MSI status of the
microsatellite sequences was scored if frameshift mutations
were observed in >40% of the homozygous markers. Because
increased instability in the repeated sequences obscured the
LOH status in most microsatellite markers, a LOH was scored
in those cases without a MSI. A reduction in the allelic inten-
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sity in the tumor tissue was scored as a LOH if the normal-
ized ratio of the heterozygous alleles had decreased to the cut-
off point of less than 0.65-fold intensity reduction.
The lost extent of a chromosomal arm was determined
based on the number of allelic losses, and was classified into
either a constitutional loss involving more than one microsatel-
lite allele or an interstitial loss involving only one allele. The
extent of the chromosomal losses in each case was scored accord-
ing to the number of constitutional chromosomal losses caus-
ing a significant reduction in the genomic dosage. According
to the classification criterion for the extent of the chromoso-
mal losses reported previously (7, 8), the intestinal-type gas-
tric carcinomas were divided into low-level (LOH-L, three
or fewer losses) and high-level (LOH-H, four or more losses)
loss groups, and the diffuse-type carcinomas were divided
into the baseline-level (LOH-B, zero or one loss), low-level
(LOH-L, two or three losses), and high-level (LOH-H, four
or more losses) loss groups.
DNA modification by sodium bisulfite
Ninety microliters of the tissue lysate were denatured with
10  L of 3 M NaOH for 15 min at 37℃. The mixture was
then modified with 1,040  L of 2.3 M sodium bisulfite and
60  L of 10 mM hydroquinone for 12 hr at 50℃, and puri-
fied using the Wizard DNA purification resin (Promega,
Madison, WI, U.S.A.) according to the manufacturer’s instruc-
tions (20). The modified DNA was finally precipitated by
adding 2.5 volumes of 100% ethanol and 1  L of salmon
testis DNA (5 mg/mL, Sigma-Aldrich, St. Louis, MO, U.S.A.).
The pellet was washed with 70% ethanol, dried, and dissolved
in 35  L of a 5 mM Tris buffer (pH 8.0). In order to avoid
repeated freezing and thawing, a 1  L aliquot of the modified
DNA solution was placed in a PCR tube and stored at -20℃.
The genomic DNA universally methylated by DNA methy-
lase (CpGenome Universal Methylated DNA, Chemicon,
Temecula, CA, U.S.A.) was used as the methylation control
DNA. The PCR DNA that had been amplified by a universal
primer (5′ -CCG ACT CGA GNN NNN NAT GTG G-3′ )
was used as the unmethylation control DNA. Universal PCR
was carried out as follows: 1 cycle of denaturation at 94℃
for 3 min, 10 cycles of 94℃ for 1.5 min, 30℃ for 2.5 min,
a ramp at 0.1℃/sec to 72℃, 72℃for 3 min and 30 cycles of
94℃ for 1 min, 62℃ for 1.5 min, 72℃ for 2 min, and 8
Fig. 1. Representative autoradiographs of the multifocal microsatellite and methylation analyses. (A) Case 10 shows a high-frequency
microsatellite instability (MSI) at more than 40% of the 15 homozygous markers in the three tumor sites (T1, 67%; T2, 73%; T3, 80%). Case
25 had a high-level loss of heterozygosity (LOH) involving chromosomes 3p, 4p, 5q, 9p, 13q, 17p, and 18q commonly shared by the three
tumor sites. Normal (N) and the corresponding tumor (T) DNAs are indicated above each allelic band. The asterisk indicates a MSI or LOH.
(B) Normal lymph node (LN), nontumoral gastric mucosa (N), and multiple tumor sites (T1, T2, and T3) have a broad range of methylated
and unmethylated amplification from the bisulfite-modified DNAs. The lanes marked by U and M indicate the PCR bands of the unmethy-
lation and methylation primer sets, respectively. The methylated and unmethylated proportion of the Maspin CpG islands and the RABGEF1
non-island CpGs was obviously different between the normal lymph node and the gastric mucosa of case 10 and 25. Case 10 with a MSI
shows diverse increases in the methylated proportion of the CpG islands of the hMLH1, Maspin, p16, and Cyclin D2 genes as well as the
non-island CpGs of the hMLH1 and RABGEF1 genes. In case 25 with a high-level chromosomal loss, the unmethylated proportion of the
CpG islands of the Maspin and CAGE genes and the non-island CpGs of the hMLH1, RABGEF1 and MAGE-A2 genes are increased in a
similar or dissimilar grade. The percentage of methylated CpGs in the template DNA calculated based on the standard MSP curve (Fig. 2)
is indicated below the lanes. The results of microsatellite and methylation analyses are summarized in Tables 2 and 5, respectively.
A B
Case 10
D3S1619
N T1*T2 T3*
Case 10
CpG island
RABGEF1
hMLH1
RASSF1A
Non-island CpG
p16
hMLH1
RABGEF1
MAGE-A2
Maspin
p16
Cyclin D2
CAGE
p15
E-cadherin
D4S2946
N T1*T2 T3*
D3S1312
N T1*T2 T3*
D3S1552
NT 1 T 2 T 3
D3S1312
NT 1 T 2 T 3
D3S1478
N T1*T2* T3
D3S1619
N T1*T2*T3*
D3S1597
NT 1 T 2 T 3
D4S230
N T1*T2*T3*
D5S519
N T1 T2 T3*
D4S1609
N T1*T2*T3*
D4S174
N T1*T2*T3*
D4S230
NT 1 T 2 T 3
D4S391
NT 1 T 2 T 3
LN N T1 T2 T3
UMUMUMUMUM
18% 1% 0% 0% 0%
34% 5% 88% 100% 100%
0% 0% 0% 0% 0%
94% 17% 31% 30% 32%
1% 2% 33% 34% 36%
0% 0% 68% 23% 0%
93% 95% 95% 94% 100%
0% 0% 0% 1% 2%
18% 26% 0% 0% 0%
36% 37% 37% 37% 38%
38% 65% 98% 69% 67%
99% 50% 97% 95% 95%
100% 98% 98% 100% 100%
0% 0% 0% 0% 0%
2% 0% 0% 0% 0%
0% 0% 0% 0% 0%
100% 38% 5% 2% 34%
0% 0% 0% 0% 0%
6% 5% 3% 5% 5%
68% 66% 38% 65% 31%
2% 1% 0% 1% 1%
0% 17% 6% 0% 0%
1% 1% 1% 2% 1%
48% 54% 33% 37% 37%
76% 46% 29% 30% 29%
100% 94% 45% 47% 28%
Case 25
LN N T1 T2 T3
UMUMUMUMUM
D5S422
N T1*T2*T3*
D8S262
N T1 T2 T3*
D5S349
NT 1 T 2 T 3
D5S409
N T1*T2*T3*
D5S346
NT 1 T 2 T 3
D5S519
N T1*T2*T3*
D5S422
N T1*T2*T3*
D8S277
N T1*T2*T3*
D8S503
N T1*T2*T3*
D8S1734
NT 1 T 2 T 3
D8S261
NT 1 T 2 T 3
D8S552
NT 1 T 2 T 3
D8S503
NT 1 T 2 T 3
D8S262
NT 1 T 2 T 3
D8S261
N T1T2*T3*
D8S1734
N T1T2*T3*
D9S200
NT 1 T 2 T 3
D9S270
N T1*T2*T3*
D9S157
N T1*T2*T3*
D9S199
N T1*T2*T3*
D9S288
N T1*T2*T3*
D9S270
N T1*T2* T3
D13S118
NT 1 T 2 T 3
D13S267
N T1*T2*T3*
D13S118
N T1*T2*T3*
D13S263
N T1*T2* T3
D13S135
NT 1 T 2 T 3
D13S286
NT 1 T 2 T 3
D13S286
N T1*T2*T3*
D18S67
N T1*T2*T3*
D17S1358
NT 1 T 2 T 3
D17S122
NT 1 T 2 T 3
TP53
N T1*T2*T3*
D17S796
NT 1 T 2 T 3
D17S1566
NT 1 T 2 T 3
D18S363
N T1*T2* T3
D18S474
NT 1 T 2 T 3
D18S67
NT 1 T 2 T 3
D18S57
NT 1 T 2 T 3
D18S70
N T1*T2*T3*
D18S363
N T1*T2*T3*
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min of elongation at 72℃.
Methylation density analysis
Methylation analysis using the radioisotope was performed
in minimal of amplification rounds in order to avoid excessive
DNA amplification. One  L of the bisulfite-modified DNA
was amplified and labeled by a hot-start PCR containing  -
32P dTTP (PerkinElmer, Boston, MA, U.S.A.) and dNTP
mixture through 32 PCR cycles. Bisulfite-modified DNAs
produced a total PCR intensity of 2-10 ng/ L by each MSP
primer set. Of the PCR products, 5  L was loaded directly
onto a nondenaturing polyacrylamide gel and visualized by
repeated autoradiography using a radioluminograph scanner.
An initial study validated the high specificity of each MSP
primer set using the methylation and unmethylation control
DNA. The standard curves for the MSP primers were plot-
ted according to the methylation and unmethylation band
intensities that were amplified from various mixtures of the
two control DNAs (Fig. 2). The proportion of the methyla-
tion and unmethylation band intensities against the total
intensity of each MSP primer set showed a linear relationship
between the percentage of the methylation and unmethyla-
tion control DNAs in the template-primer mixtures. Based
on the standard curve of the control MSP bands, the reciprocal
proportion of methylation and unmethylation bands (Fig. 1B)
was graded as complete unmethylation (0-20% methylation,
zero methylation), low density methylation (21-40% methy-
lation, one methylation), moderate density methylation (41-
60% methylation, two methylation), high density methyla-
tion (61-80% methylation, three methylation), and complete
methylation (81-100% methylation, four methylation).
Methylation- and unmethylation-specific PCR and bisul-
fite sequencing
The MSP primer sets were designed in order to assess the
small fragment less than 150 bp, which stably amplified
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Fig. 2. Standard curves for the methylated and unmethylated MSP amplification. The genomic DNA universally methylated by DNA methy-
lase and the genome-wide-PCR DNA amplified by a universal primer were used as the positive controls for the methylation and unmethy-
lation DNAs, respectively. The variable mixtures of the two opposite control DNAs based on their PCR intensity of 20 ng/ L were amplified
using a set of MSP primers. The band intensities of the methylation (M, closed circle) and unmethylation (U, open circle) primer sets for the
CpG islands of the hMLH1 (A), Maspin (B), and CAGE (C) genes and the non-island CpGs of hMLH1 gene (D) are plotted along with the
relative proportion against the total band intensity. The amplification intensity ratio of each primer set is linearly increased with the increas-
ing percentage of the corresponding control DNA in the MSP template-primer mixtures. The methylation-unmethylation proportion of the
template DNA was distinguished into five grades (0-20% methylation, 21-40% methylation, 41-60% methylation, 61-80% methylation, and
81-100% methylation) based on the reciprocal curves of the methylation and unmethylation bands. The band intensity ratio of each MSP
primer set is listed in Table 1.
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the template DNAs from the obtained formalin-fixed paraf-
fin-embedded tissues. The primer sequences were selected
using a MethPrimer software (http://www.urogene.org/meth-
primer/), and were checked for any sequence redundancy by
BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/). Two
different CpG regions adjacent to the transcription start site
were accessed in this study. The CpG islands at a CpGObs/Exp
ratio >0.6 resided within the extragenic regions 1 kb proxi-
mal to the genic regions, whereas the upstream regions more
than 1 kb distant from the genes showed a low number of
CpG site (Table 1). The MSP primer sets for the CpG islands
of the hMLH1 (21), RASSF1A (22), p15 (23) genes and the
non-island CpGs of MAGE-A2 (24) gene were based on those
described elsewhere.
Two or three CpG sites within the MSP primer sequences
were found to amplify the specific methylation and unmethy-
lation band intensities from the control DNAs. The non-island
CpGs, which had a relatively low CpG content, was insuffi-
cient to facilitate the primer design in some cases. These CpG
primer sets introduced the non-specific bands to the coun-
terpart control DNAs. Thirteen out of the 17 primer sets
tested amplified only a specific band intensity ratio ≥0.9
from both the methylation and the unmethylation control
DNAs (Table 1). Finally, a panel of 13 MSP primer sets were
selected from the upstream regions adjacent to the p15, p16,
hMLH1, E-cadherin, RASSFIA, MAGE-A2, CAGE, Maspin,
and Cyclin D2 genes, in which one or more reports described
the hypo- or hypermethylation changes in gastric carcinomas,
as well as an arbitrarily selected RABGEF1 gene.
The methylation composition of each template DNA copy
was analyzed by bisulfite sequencing. The methylation-un-
methylation common primer sets encompassing the MSP
primer sequences were used. The PCR products common to
the methylated and unmethylated CpGs were cloned into
the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, U.S.A.),
and the PCR clones from each genomic DNA were cycle-
sequenced using a BigDye Terminator Kit (PE Biosystems,
Foster City, CA, U.S.A.) and an ABI automated DNA se-
quencer (PE Biosystems, Warrington, U.K.).
Statistical analysis
The statistical comparisons of the clinicopathological fea-
tures between the different microsatellite genotypes were
performed using an independent t test and a  2 test or Fisher’s
exact test. Mann-Whitney U and Kruskal-Wallis nonpara-
metric tests were used to compare the methylation status
according to the level of chromosomal losses and the clinico-
pathological parameters. Two-sided p-values less than 0.05
were considered significant.
RESULTS
Multifocal analysis of microsatellite alterations
Of the 40 gastric carcinomas, three had a high-frequency
MSI at more than 40% of the homozygous alleles in multi-
ple tumor sites examined (Fig. 1A, Table 3). A total of 411
chromosomal losses were detected in 111 tumor sites from
CpGObs/Exp Coding
gene
Chromosome
locus
GC%
5′ position*
UM
Intensity ratio
�
U U/M M
CpG island
RABGEF1 7q11.21 0.95 63.5 -284 -282 0.90 0.46/0.54 0.91
hMLH1 3p22 0.86 68 -664 -669 0.94 0.48/0.52 0.93
RASSF1A 3p21.3 0.81 70 106 118 0.92 0.46/0.54 0.93
Maspin 18q21.43 0.8 45 -314 -309 0.93 0.51/0.49 0.94
p16 9p21 0.79 74.5 -218 -218 0.91 0.47/0.53 0.91
Cyclin D2 12p13.32 0.79 72 -1,229 -1,226 0.92 0.48/0.52 0.93
CAGE Xq22.11 0.77 55 -63 -92 0.94 0.48/0.52 0.94
p15 9p21 0.74 70 95 99 0.91 0.48/0.52 0.91
E-cadherin 16q22.1 0.62 69.5 -106 -104 0.92 0.49/0.51 0.94
Non-island CpG
Cyclin D2 12p13.32 0.59 52.5 -2,326 -2,325 0.75 0.58/0.42 0.54
MAGE-A2 Xq28 0.52 66 -389 -386 0.74 0.45/0.55 0.90
p16 9p21 0.48 61.5 -1,581 -1,576 0.90 0.47/0.53 0.93
CAGE Xq22.11 0.40 50.5 -1,447 -1,447 0.56 0.37/0.63 0.93
hMLH1 3p22 0.38 51.5 -1,107 -1,107 0.93 0.51/0.49 0.95
Maspin 18q21.43 0.38 51 -972 -972 0.56 0.39/0.61 0.78
RABGEF1 7q11.21 0.29 65 -8,630 -8,628 0.91 0.48/0.52 0.90
MAGE-A2 Xq28 0.18 58.5 -1,440 -1,439 0.90 0.54/0.46 0.91
Table 1. CpG dinucleotides examined by the methylation-specific polymerase chain reaction
*The genomic positions were calculated from the July 2003 human genome reference sequence. 
�
The relative proportion of the unmethylation (U) and
methylation (M) primer sets against the total band intensity. The nucleotide sequences and PCR condition of each primer set are provided in the Table 2.Chromosomal Loss and CpG Methylation Change in Gastric Carcinoma 795
37 MSI-negative cases. Of these, 389 (95%) were counted
as being constitutional losses involving more than one micro-
satellite marker on a chromosomal arm. Thirteen (35%) out
of the 37 LOH-positive gastric carcinomas were found to be
composed of genetically different subclones in terms of the
intratumoral LOH clonality. Six cases had heterogeneous
LOHs involving the upper and lower opposite alleles on the
same chromosome.
In a comparison of the LOH heterogeneity rate (Table 4),
the mixed- and diffuse-type gastric carcinomas (61%), ad-
vanced-stage diseases (69%) and the small sized tumors ≤5
cm in diameter (69%) showed frequent LOH heterogeneity.
However, as a result of the reciprocal losses of the opposite
alleles on the same chromosomes, a difference in the genomic
dosage reduction between the heterogeneous tumor sites was
no greater than one chromosomal loss. In most LOH-positive
cases (35 out of 37), the same or a similar number of chromo-
somal losses detected in heterogeneous tumor sites was clas-
sified into the same category of chromosomal losses (Table 3).
Case 28, who contained two (low level) and four (high level)
losses, was defined as a LOH-H genotype detected in two of
the three tumor sites examined. Case 22 containing no con-
stitutional chromosomal losses was classified into a LOH-B
genotype based on the predominance of a diffuse-type his-
tology. Consequently, 4 LOH-B (10%), 16 LOH-L (40%),
17 LOH-H (42.5%), and 3 MSI (7.5%) cases were identified
in the 40 surgical specimens examined. In a comparison of
the clinicopathological variables between the LOH-H and
LOH-L gastric carcinomas (Table 5), a lymphatic invasion
(p=0.005) and advanced stage (p=0.002) were significantly
associated with the LOH-H cases.
Methylation status of the nontumoral tissues
A total of 13 CpG regions examined showed various methy-
lation densities in the nontumoral tissues including the gas-
tric mucosa, gastric intestinal metaplasia and lymph nodes,
which variably changed in the heterogeneous tumor sites (Fig.
Forward (5′ to 3′ ) Reverse (5′ to 3′ ) Size Tm (°C)
CpG island
RABGEF1 U AAGTTGGAAGTAGGGATTGAGT CAAAATAAAATACCACCCTAACA 131 58
M GTCGGAAGTAGGGATTGAGC GAAATAAAATACCGCCCTAACG 128 58
hMLH1 U TTTTGATGTAGATGTTTTATTAGGGTTGT ACCACCTCATCATAACTACCCACA 124 58
M ACGTAGACGTTTTATTAGGGTCGC CCTCATCGTAACTACCCGCG 112 58
RASSF1A U TTTGGTTGGAGTGTGTTAATGTG CAAACCCCACAAACTAAAAACAA 105 58
M GTGTTAACGCGTTGCGTATC AACCCCGCGAACTAAAAACGA 93 58
Maspin U GAATATTTTATTTTTTGGTTTTGTG AAAAAACCTCCAACATATTCA 111 56
M TTATTTTTCGGTTTTGCG AAAAAACCTCCAACATATTCG 104 54
p16 U TGTTTATTTTTGTTTTGTAGGTG AAAACTCAAAACCATTCCAA 130 56
M TGTTTATTTTCGTTTCGTAGGC AAAACTCAAAACCGTTCCGA 129 58
Cyclin D2 U GGAGGTGAAGAAATGTTATTAGATT TCTCCCTAAAAACCAACTACA 140 59
M GGTGAAGAAACGTTATTAGATC TCCCTAAAAACCGACTACG 134 55
CAGE U TGGTTTTTGGGGTAATTTTTGT CAAATCTACAACCTATTTCCCA 105 57
M TTTTATACGATTCGGAATTCGAC CAAATCTACGACCTATTTCCCG 136 58
p15 U TGTGATGTGTTTGTATTTTGTGGTT CCATACAATAACCAAACAACCAA 154 58
M GCGTTCGTATTTTGCGGTT CGTACAATAACCGAACGACCGA 148 58
E-cadherin U GGTGAATTTTTAGTTAATTAGTGGTAT TCACAAATACTTTACAATTCCAACA 108 56
M TGAATTTTTAGTTAATTAGCGGTAC ACAAATACTTTACAATTCCGACG 104 58
Non-island CpG
p16 U TTGGGATTAGGTTTAGTTTTGG CTATAAAACCCTATCAACTCACACT 130 58
M TCGGGATTAGGTTTAGTTTCG AAACCCTATCGACTCACGCT 125 60
hMLH1 U GATTTTAGGATTGTTGATATGAGT AAACTACCTCCTAATCTTTATCCA 126 58
M GATTTTAGGATTGTCGATATGAGC AACTACCTCCTAATCTTTATCCG 125 58
RABGEF1 U ATTAAGGGTAGTTAGAATGTTTGG AAACCCAAAACTCACTTATAAACAA 124 58
M TAAGGGTAGTTAGAACGTTCGG CCCAAAACTCGCTTATAAACG 119 60
MAGE-A2 U GTTAGGTTGTTGTTTAGGGT CCAAAAAAATCACAAACCCA 92 59
M GCGTTTGTTTTTTTTCGTCGAC AAATCACGAACCCGAATATAACG 108 61
Common primer
hMLH1* GAAGGAGGTTAYGGGTAAG TAATCTATCRCCRCCTCATC 155 60
hMLH1
� TGTTGTTTGTAGGGATTTTAGGATTG CCTATAAAAACTACCTCCTAATCT 146 57
p16* AATTGTAGATTGGGATTTAYG CRTACRCAAAACTCAAAACC  169 56
p16
� CAAACCTCACTTTCCTCCC GGGTGTGTGTTAGAGGATT 197 60
MAGE-A2 GGGTGAGGTTYGTTTTAG TCCACCCTTACCRTAAACCC 189 57
Table 2. Sequences and PCR condition of the methylation-specific PCR primer sets
*CpG island area. 
�
Non-island CpG area. Y and R represent T+C and A+G nucleotide, respectively.796 S.-J. Hong, Y.-H. Kim, Y.-D. Choi, et al.
1B). The multifocal MSP analysis results are summarized in
Table 6. Initially, a methylation density in the different non-
tumoral tissues was compared (Fig. 3). The moderate to com-
plete methylation of the hMLH1 (p=0.005) and Maspin (p<
0.0001) CpG islands and the RABGEF1 non-island CpGs
(p<0.0001) were significantly higher in the normal lymph
nodes than in the gastric mucosa. The low density methyla-
tion of the Maspin gene at the gastric mucosa of intestinal
metaplasia was significantly increased than the gastric mucosa
without intestinal mucosa (p=0.019). In contrast, the high
density methylation of the hMLH1 non-island CpGs was
significantly increased in the gastric mucosa with intestinal
metaplasia as compared with the gastric mucosa without
intestinal metaplasia (p=0.002). The methylation status of
the CAGE CpG islands and the p16 non-island CpGs were
similar in the gastric mucosa and lymph nodes.
Case
No.
3p 4p 5q 8p 9q 13q 17p 18q Histological type Tumor stage Genotype*
LOH-H Intestinal type Stage III
LOH-H Intestinal type Stage IV
LOH-H Intestinal type Stage III
LOH-H Mixed type Stage II
LOH-H Intestinal type Stage III
LOH-H Intestinal type Stage III
LOH-H Mixed type Stage III
LOH-H Intestinal type Stage I
LOH-H Intestinal type Stage III
LOH-H Intestinal type Stage II
LOH-H Mixed type Stage IV
LOH-H Diffuse type Stage III
LOH-H Mixed type Stage IV
LOH-H Diffuse type Stage IV
LOH-H Diffuse type Stage IV
LOH-H Diffuse type Stage III
LOH-H Intestinal type Stage II
LOH-L Mixed type Stage II
LOH-L Diffuse type Stage II
LOH-L Intestinal type Stage I
LOH-L Diffuse type Stage III
LOH-L Intestinal type Stage II
LOH-L Intestinal type Stage II
LOH-L Intestinal type Stage II
LOH-L Intestinal type Stage I
LOH-L Diffuse type Stage I
LOH-L Intestinal type Stage I
LOH-L Intestinal type Stage I
LOH-L Intestinal type Stage I
LOH-L Intestinal type Stage III
LOH-L Intestinal type Stage III
LOH-L Intestinal type Stage I
LOH-L Intestinal type Stage I
LOH-B Diffuse type Stage IV
LOH-B Diffuse type Stage III
LOH-B Diffuse type Stage II
LOH-B Mixed type Stage IV
MSI Intestinal type Stage II
MSI Mixed type Stage II
MSI Mixed type Stage I
16
25
26
36
7
21
37
38
3
29
24
48
50
41
12
14
28
9
31
35
46
33
34
6
44
11
15
39
32
40
1
5
23
30
27
49
22
10
2
43
Table 3. The results of the multifocal microsatellite analysis of gastric carcinomas (n=40)
*The classification of the microsatellite genotype is detailed in the ‘‘Materials and Methods’’ section. Each rectangle is divided into three parts (     ) indi-
cating three tumor sites, T1, T2, and T3.    constitutional chromosomal loss involving more than one microsatellite marker,    interstitial chromosomal
loss involving one microsatellite marker,    reciprocal loss of upper and lower allele,    positive for microsatellite instability,    negative for a loss of het-
erozygosity.
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Comparison of methylation density between the paired
normal and tumor tissues
When comparing the methylation status of the nontumoral
gastric mucosa and their corresponding heterogeneous tumor
sites (Fig. 3), the zero to two methylation of the CpG islands
of the Maspin (p=0.031) and CAGE (p=0.005) genes as well
as the non-island CpGs of the MAGE-A2 (p<0.0001) and
RABGEF1 (p=0.004) genes was significantly higher in the
tumor tissues. The tumor tissues demonstrated significant
increases in the methylation density at the hMLH1 (p=0.020),
p16 (p=0.005), and RASSF1A (p=0.015) CpG islands that
were completely unmethylated in the normal tissues. The
CpG islands of the RABGEF1, p15 and E-cadherin genes suf-
fered few methylation differences in tumor tissues.
The methylation status of the tumor tissues was analyzed
separately according to the four microsatellite genotypes,
LOH-H, LOH-L, LOH-B, and MSI (Fig. 3). The methyla-
tion density at the CpG islands of the Maspin (p=0.007) and
CAGE (p=0.010) genes in addition to all of the non-island
CpGs upstream of the p16 (p=0.013), hMLH1 (p=0.003),
MAGE-A2 (p<0.0001) and RABGEF1 (p<0.0001) genes
were significantly decreased in the LOH-H tumor sites. The
LOH-L tumor sites showed significant increased methylation
in the CpG islands of the hMLH1 (p=0.012), RASSF1A (p=
0.037), p16 (p=0.049) and Cyclin D2 (p=0.034) genes, and
in the non-island CpGs of the p16 (p=0.038) and hMLH1
(p=0.005) genes. The increased methylation density of the
six CpG regions in the LOH-L cases was significantly dif-
ferent from the unchanged (CpG islands) or decreased (non-
island CpGs) methylation density in the LOH-H cases. All
the p-values are listed in the Table 7.
In both the LOH-B and MSI cases, the methylation den-
sity tended to be higher in the CpG islands of the RASSF1A,
p16, and Cyclin D2 genes as well as in the non-island CpGs
of the p16 and hMLH1 genes. The CpG islands of the hMLH1
gene were mainly hypermethylated in the nine tumor sites
from the three MSI-positive cases (complete methylation in
8 tumor sites and incomplete methylation in 1 tumor sites).
Unmethylated E-cadherin CpG islands were detected in the
Homoge-
neous
LOH (%) No. of cases 37
24
Heteroge-
neous 
LOH* (%)
13
Different
losses* 
(per case)
10 (0.77)
Age (yr)
≤55 10 5 (21) 5 (38) 3 (0.60)
56-65 16 12 (50) 4 (31) 4 (1.00)
>65 11 7 (29) 4 (31) 3 (0.75)
Sex
Male 24 16 (67) 8 (62) 7 (0.88)
Female 13 8 (33) 5 (38) 3 (0.6)
Tumor size
≤5 cm 19 10 (42) 9 (69) 7 (0.78)
>5 cm 18 14 (58) 4 (31) 3 (0.75)
Histological type
Intestinal 21 16 (66) 5 (39) 3 (0.60)
Diffuse 10 4 (17) 6 (46) 5 (0.83)
Mixed 6 4 (17) 2 (15) 2 (1.00) 
Tumor stage
Early stage 18 14 (58) 4 (31) 1 (0.25)
Advanced stage 19 10 (42) 9 (69) 9 (1.00)
Chromosomal loss
Baseline level 4 2 (8) 2 (15) 1 (0.50)
Low level 16 12 (50) 4 (31) 2 (0.50)
High level 17 10 (42) 7 (54) 7 (1.00)
Table 4. Clonality of loss of heterozygosity (LOH) detected by
the multifocal analysis on 37 gastric carcinomas
*The reciprocal loss of the upper and lower opposite alleles on the same
chromosomes was not counted as a different chromosomal loss.
LOH-H Microsatellite 
genotype*
No. of patients
33
17
LOH-L
p value
�
16
LOH-B
4
MSI
3
Age (yr) 0.507
Mean±SD 60.1 61.4 58.5 53.3 69.0
±10.8 ±10.1 ±11.6 ±7.4 ±13.5
Tumor size, cm  0.409
Mean±SD 5.3 5.7 4.9 4.92 8.5
±2.7 ±2.5 ±2.8 ±2.6 ±4.4
Sex 0.451
Male 22 12 10 2 1
Female 11 5 6 2 2
Location 0.249
Cardia 2 0 2 0 0
Body 7 3 4 4 0
Antrum 24 14 10 0 3
Lauren classification 0.310
Intestinal 21 9 12 0 1
Diffuse 7 4 3 3 0
Mixed 5 4 1 1 2
Differentiation 0.084
Well 4 0 4 0 0
Moderate 18 11 7 0 1
Poor 11 6 5 4 2
Growth pattern 0.282
Infiltrative 22 13 9 1 1
Expanding 0 0 0 0 1
Mixed 13 4 7 3 1
Venous invasion 0.227
Yes 3 3 0 2 0
No 30 14 16 2 3
Lymphatic invasion 0.005
Yes 19 14 5 4 2
No 14 3 11 0 1
Tumor stage 0.002
Early stage 17 4 13 1 3
Advanced stage 16 13 3 3 0
Table 5. Clinocopathological characteristics of microsatellite
genotypes in gastric carcinomas
*The classification of microsatellite genotypes is detailed in the ‘‘Materials
and Methods’’ section. 
� p-values were calculated between the LOH-L
and LOH-H cases by an independent t-test for the age and tumor size
variables and by a Fisher’s exact test or a 
2-test for the other variables.798 S.-J. Hong, Y.-H. Kim, Y.-D. Choi, et al.
LOH-B and MSI cases. The statistical analysis results are not
shown for the small number of LOH-B and MSI cases.
Relationships between the methylation differences and
the clinicopathological features
A difference in the methylation density between the paired
nontumoral gastric mucosa and each tumor site was graded
U1 through to U4 according to the decreased methylation
degree and M1 through to M4 according to the increased
methylation degree. The mean value of the methylation dif-
ferences in the three tumor sites was correlated with the clini-
copathological features in a subset of gastric carcinomas with
low- and high-level chromosomal losses (Table 8). The hMLH1
(p=0.034), RASSF1A (p=0.031), and p16 (p=0.031) CpG
islands and the four non-island CpGs (p16, p=0.002; hMLH1,
p<0.0001; RABGEF1, p=0.015; MAGE-A2, p<0.0001)
showed statistical significances in the pattern of methylation
RABGEF1
hMLH1
RASSF1A
Maspin
p16
Cyclin D2
CAGE
p15
E-cadherin
p16
hMLH1
RABGEF1
MAGE-A2
16
25
26
36
7
21
37
38
3
29
24
48
50
41
12
14
28
9
31
35
46
33
34
6
44
11
15
39
32
40
1
5
23
30
27
49
22
10
2
43
Table 6. Summary of the multifocal methylation analysis on gastric carcinomas 
The methylation status of each case is indicated by five parts in the order of the lymph node, normal mucosa, and the three tumor sites.    0-20% methyla-
tion, 21-40% methylation,    41-60% methylation,    61-80% methylation,    81-100% methylation. 
CpG island Non-island CpG
Case
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Fig. 3. Methylation profiles of the CpG islands and non-island CpGs in the nontumoral and tumoral tissues. The nontumoral gastric mucosa
is grouped according to the presence and absence of the intestinal metaplasia. The tumor tissues are grouped into four microsatellite geno-
types. The classification of the microsatellite genotypes is detailed in the ‘‘Materials and Methods’’ section. The CpG methylation status in
each tissue group is given as a percentage of five grades. The p-value was calculated using the Mann-Whitney U test. There were *sig-
nificant differences in methylation density between the lymph node and gastric mucosa, between the presence and absence of intestinal
metaplasia, and between the LOH-H and LOH-L groups. The heterogeneous tumor sites showed significant 
� decreased methylation and
� increased methylation density compared with the gastric mucosa. 
�Statistical comparison was not shown due to the small number of
LOH-B and MSI cases. All p-values are listed in the Table 7.
Lymph
node
CpG island
RABGEF1
Non-island CpG
p16
hMLH1
RABGEF1
MAGE-A2
Grade of methylation status
hMLH1
RASSF1A
Maspin
p16
Cyclin D2
CAGE
p15
E-cadherin
Gastric
mucosa
Intestinal metaplasia
No Yes
Gastric
Tumor
Genotype
LOH-H LOH-L LOH-B
� MSI
�
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
100
50
0
(%)
*
�
�
�
�
�
��
�
� �
��
�
� �
� �
�
�
*
*
*
*
*
*
* *
*
*
*
*
(                                                                                                                     ) 81-100% 61-80% 41-60% 21-40% 0-21%800 S.-J. Hong, Y.-H. Kim, Y.-D. Choi, et al.
differences between the LOH-H and LOH-L cases.
In a subset of gastric carcinomas with low-level or high-
level chromosomal losses, the decreased methylation differ-
ences in the non-island CpGs of p16, hMLH1, and MAGE-
A2 genes correlated with the mixed histological type, a lym-
phatic invasion, and an advanced tumor stage (p<0.05) (Table
8). The decreased methylation differences in the CpG islands
of the Maspin genes were associated with the large-sized tumors
(p=0.012). In contrast, the increased methylation differences
in the p16 CpG islands correlated with well differentiation
(p=0.039), a small size (p=0.042), a non-lymphatic invasion
(p=0.031) and an early tumor stage (p=0.042). The relation-
ships between the increased methylation differences in the
CpG islands other than p16 and either a non-lymphatic inva-
sion (hMLH1, p=0.035; RASSF1A, p=0.031) or an early
tumor stage (RASSF1A, p=0.042) also reached borderline-
level statistical significance.
Methylation heterogeneity
A total of 1,560 pairs of methylation and unmethylation
bands were obtained from the 120 heterogeneous tumor sites
using MSP analysis on the 13 CpG regions, of which 305
(19%), 267 (17%), and 991 (64%) demonstrated decreased
methylation, increased methylation, and no methylation
changes, respectively. When analyzing the pattern and grade
of methylation differences in three heterogeneous sites of each
case (Fig. 4A), the grade of increased and decreased methy-
lation differences were similar (8% and 11%) or dissimilar
(12% and 11%). However, no gastric carcinomas showed
both the increased and decreased methylation in heteroge-
neous tumor sites simultaneously.
A large fraction (59%) of methylation differences tended
to cluster in a range of U1 and M1 low-grade differences,
whereas a complete difference (M4 and U4) of the methyla-
tion status was detected in only five normal mucosa-tumor
pairs (0.9%) (Fig. 4B). The three tumor-cell-content groups,
70-79% (221 tumor sites), 80-89% (962 tumor sites), and
≥90% (377 tumor sites), demonstrated varying grades of
methylation differences (Fig. 4C). The U1 and M1 low-grade
differences and the U3 and M3 high-grade differences were
similarly increased in the high tumor-cell-content group (63%
and 12%) when compared with the low tumor-cell-content
group (57% and 8%). 
The CpG islands and non-island CpGs of the p16, hMLH1,
and MAGE-A2 genes were amplified and cloned using the
methylation-unmethylation common primers encompassing
the MSP primer sequences (Fig. 5). The methylation densities
of the individual PCR clones examined using the MSP primer
sets were different (Fig. 5A), and the number and position
of the methylated CpGs identified by bisulfite sequencing
were heterogeneous (Fig. 5B). The pooled PCR clones showed
a similar proportion of methylated and unmethylated ampli-
fications to the corresponding genomic DNA (Fig. 5 A).
DISCUSSION
The aforementioned studies have reported frequent gene-
specific hypermethylation in the intestinal metaplasia and
adenoma (15), whereas chromosomal losses were rare in the
intestinal metaplasia and low-grade dysplasia (25). Given the
multistep carcinogenesis, the tumor progenitor cells acquir-
ing the hypermethylation in the initial step appear to sub-
clonally expand via further hypermethylation or chromoso-
mal losses (genome dosage reduction) providing a selective
growth advantage. The previous results that <10% of colo-
rectal carcinomas show frequent methylation of the CpG
Lymph node 
vs.
gastric mucosa
Intestinal 
metaplasia
No vs. yes
Gastric mucosa
vs.
Tumor
Gastric mucosa
vs. LOH-H 
genotype tumor
Gastric mucosa
vs. LOH-L 
genotype tumor
LOH-H vs. 
LOH-L 
genotype tumor
CpG island
RABGEF1 0.088 0.463 0380 0.360 1.000 0.359
hMLH1 0.005* 0.769 0.020* 0.639 0.012* 0.001*
RASSF1A 1.000 1.000 0.015* 1.000 0.037* <0.0001*
Maspin <0.0001* 0.019* 0.031* 0.007* 0.567 0.197
p16 1.000 1.000 0.005* 1.000 0.049* <0.0001*
Cyclin D2 0.784 0.444 0.114 0.096 0.034* <0.0001*
CAGE 0.362 0.499 0.005* 0.010* 0.263 0.867
p15 1.000 1.000 0.132 0.582 0.310 0.233
E-cadherin 0.151 0.698 0.562 0.713 0.463 0.080
Non-island CpG
p16 0.707 0.392 0.695 0.013* 0.038* <0.0001*
hMLH1 0.142 0.002* 0.211 0.003* 0.005* <0.0001*
RABGEF1 <0.0001* 0.279 0.004* <0.0001* 0.455 <0.0001*
MAGE-A2 0.317 0.173 <0.0001* <0.0001* 0.084 <0.0001*
Table 7. P values of the statistical analysis presented in Figure 3
*p values <0.05.Chromosomal Loss and CpG Methylation Change in Gastric Carcinoma 801
islands at the methylated-in-tumor (MINT) loci, but no MSI,
which is associated with a poor prognosis (16). In this study,
the four LOH-B cases detected in 10% of gastric carcinomas
examined, which have been reported to be associated with
poor prognosis (7, 8), shows a tendency toward an increase in
methylation density. These findings on colon and gastric car-
cinomas similarly suggest that a subset of high-risk gastric
carcinomas develop largely depending on methylator phe-
notype.
The methylation density at the CpG islands of the Maspin
and CAGE genes as well as the non-island CpGs of the MAGE-
A2 and RABGEF1 genes were decreased in the tumor tissues,
which were significantly different from the normal tissues
(Fig. 3) in similarity with previous studies (24, 26, 27). A
tendency toward decreased methylation differences in these
CpG islands and non-island CpGs was found to be signifi-
cantly associated with the LOH-H cases but not with the
LOH-L cases (Table 8). Interestingly, the methylation dif-
ferences at the non-island CpGs of the p16 and hMLH1 genes
that were incompletely methylated in the normal tissues
tended to be decreased in the LOH-H cases, and they were
further increased in LOH-B, LOH-L, and MSI cases (Fig. 6).
The extragenic regions upstream of a gene appear to formu-
late a distance-dependent methylation gradient, which is
easily dislodged for hypomethylation as well as hypermethy-
lation. The hypomethylation compensating for the chromo-
somal losses can explain why the MSI inversely correlates with
the chromosomal losses (7, 28). This inverse relationship might
Genotype
High-level U0.06 U0.06 0 U0.82 0 U0.12 U0.71 0 U0.00 U0.71 U0.71 U1.00 U2.12
Low-level 0 M0.75 M0.31 U0.13 M0.56 M0.25 U0.25 M0.13 M0.06 M0.88 M0.88 U0.13 U0.38
p value 0.332 0.034* 0.031* 0.077 0.031* 0.120 0.199 0.303 0.665 0.002* < 0.0001* 0.015* < 0.0001*
Age
≤55 U0.13 M0.25 0 U0.37 0 U0.13 U0.25 0 M0.13 U0.13 M0.13 U0.63 U1.38
56-65 0 M0.36 M0.07 U0.64 M0.57 M0.07 U0.71 M0.14 0 M0.21 M0.14 U0.36 U1.21
> 65 0 M0.36 M0.36 U0.36 M0.09 M0.18 U0.36 0 0 M0.36 U0.09 U0.82 U1.27
p value 0.210 0.984 0.151 0.919 0.291 0.780 0.545 0.507 0.721 0.710 0.974 0.651 0.883
Sex
Male 0 M0.09 M0.09 U0.36 M0.36 M0.18 U0.50 M0.09 M0.09 M0.05 U0.09 U0.64 U1.36
Female U0.09 M0.82 M0.27 U0.72 M0.09 U0.18 U0.45 0 U0.09 M0.45 M0.36 U0.45 U1.09
p value 0.157 0.121 0.418 0.237 0.637 0.184 0.858 0.480 0.220 0.439 0.467 0.492 0.627
Lauren classification
Intestinal 0 M0.52 M0.24 U0.33 M0.43 M0.19 U0.67 M0.09 M0.10 M0.57 M0.38 U0.48 U1.10
Diffuse U0.14 M0.29 0 U0.42 0 U0.29 M0.43 0 U0.29 U0.43 M0.28 U0.57 U0.57
Mixed 0 U0.40 0 U1.20 0 0 U0.20 0 M0.20 U0.60 U1.60 U1.00 U3.00
p value 0.156 0.192 0.284 0.498 0.285 0.172 0.388 0.751 0.052 0.043* 0.020* 0.560 0.011*
Differentiation
Well 0 M0.25 M0.25 M0.25 M1.00 M0.50 0 0 M0.25 M1.25 M1.00 0 0
Moderate 0 M0.33 M0.17 U0.50 M0.28 M0.17 U0.78 M0.11 M0.06 M0.16 U0.33 U0.61 U1.78
Poor U0.09 M0.36 M0.09 U0.64 0 U0.27 U0.18 0 U0.09 U0.18 M0.36 U0.73 U0.91
p value 0.368 1.000 0.723 0.348 0.039* 0.093 0.200 0.659 0.314 0.123 0.148 0.352 0.045*
Tumor size
≤5 cm 0 M0.53 M0.12 0 M0.53 M0.24 U0.71 M0.12 M0.06 M0.35 M0.29 U0.59 U1.12
> 5 cm U0.06 M0.13 M0.19 U1.00 0 U0.13 U0.25 0 M0.01 U0.01 U0.19 U0.56 U1.44
p value 0.303 0.183 0.899 0.012* 0.042* 0.136 0.288 0.332 0.665 0.389 0.221 0.819 0.536
Lymphatic invasion
Yes U0.05 U0.05 0 U0.68 0 U0.11 U0.47 0 U0.05 U0.37 U0.42 U0.84 U1.95
No 0 M0.77 M0.31 U0.31 M0.54 M0.23 U0.46 0 M0.15 M0.92 M0.62 U0.15 U0.38
p value 0.408 0.035* 0.031* 0.669 0.031* 0.152 0.936 1.000 0.153 0.006* 0.017* 0.078 0.002*
Stage
Early 0 M0.65 M0.29 U0.47 M0.53 M0.12 U0.35 M0.12 M0.18 M0.82 M0.53 U0.24 U0.65
Advanced U0.06 M0.00 0 U0.50 0 U0.00 U0.63 0 U0.13 U0.50 U0.44 U0.94 U1.94
p value 0.303 0.099 0.042* 0.758 0.042* 0.387 0.442 0.332 0.179 0.002* 0.023* 0.070 0.006*
Table 8. Relationships between the methylation differences and either the genotype or the clinocopathological features in a subset of
gastric carcinomas with low-level (16 cases) and high-level (17 cases) chromosomal losses
CpG island Non-island CpG
RABGEF1
hMLH1
RASSF1A
Maspin
p16
Cyclin D2
CAGE
p15
E-cadherin
p16
hMLH1
RABGEF1
MAGE-A2
A mean value of the increased methlation (M1-4) or decreased methylation (U1-4) differences in each genotype or phenotype group was calculated
based on methylation differences between one normal site and three tumor sites in each case. *p values <0.05.802 S.-J. Hong, Y.-H. Kim, Y.-D. Choi, et al.
result from the hypomethylation effect of chromosomal loss
on the hMLH1 promoter region in which hypermethylation
silence the mismatch repair gene and induce the MSI.
The methylation density at the non-island CpGs of the
RABGEF1 gene arbitrarily selected in this study was signif-
icantly decreased in the LOH-H cases but there was no sig-
nificant relationship with the clinicopathological features.
Given the genome-wide influence of a dosage compensation
mechanism that maintains the X-to-autosomal chromosome
ratio (10, 11), the hypomethylation can occur in the cancer-
related as well as cancer-unrelated genes in association with
high-level chromosomal losses. Therefore, the high-grade
hypomethylation compensating for the high-level dosage
reduction are likely to surpass the initial hypermethylation
and to drive the progression of high-risk gastric carcinomas
independent of the hypermethylation status (Fig. 7). This
supports the previous study of colorectal cancer that hyper-
methylation and hypomethylation separately contribute to
the process of carcinogenesis (29).
The increased methylation differences in the p16, hMLH1,
and RASSF1A CpG islands were statistically significant at
well differentiation, no lymphatic invasion, and the early tumor
stage (Table 8). The same increased methylation differences
observed frequently in both the LOH-B and LOH-L cases
were paradoxical, because the two genotypes represent high-
risk and low-risk gastric carcinomas, respectively (Fig. 3).
Moreover, the decreased methylation differences in the non-
island CpGs adjacent to the p16 and hMLH1 genes were asso-
ciated with the advanced tumor stage and a lymphatic inva-
sion (Table 8). These paradoxical relationships between epi-
genetic alterations and malignant phenotypes can be explained
by the dynamic pathways composed of preceding hyperme-
thylation, irreversible chromosomal loss, and compensative
hypomethylation. The gene-specific hypermethylation changes
may initiate the tumor formation in a precancerous lesion
Fig. 4. Methylation heterogeneity on gastric carcinomas detected by multifocal analysis. The methylation status of the 13 CpG regions is
detailed in Table 6. (A) The grade and pattern of the methylation differences in a given CpG region in different tumor sites from a given
gastric carcinoma were compared. (B) The methylation differences detected in individual tumor sites are shown separately according to
the grade of the methylation differences. (C) The grades of the methylation differences given as percentage were compared between
different tumor-cell-content groups. The differences in the methylated-unmethylated proportion between the paired normal and heteroge-
neous tumor sites were graded U1-U4 decreased methylation differences and M1-M4 increased methylation differences.
Fig. 5. Heterogeneous methylation profiles of the p16, hMLH1, and
MAGE-A2 CpG regions. PCR products common for methylated
and unmethylated CpGs were cloned and ten clones were ran-
domly selected. The individual and pooled clones were amplified
by the MSP primer sets (A). The individual PCR clones generated
heterogeneous methylation densities in the MSP analysis. The
pooled PCR clones showed similar MSP patterns with those of the
corresponding genomic DNAs listed in Table 6. Five PCR clones
from each genomic DNA generating different or no MSP band
intensities were sequenced (B). PCR primers specific for the un-
methylation (     ) and methylation (    ), and common (    ) for the
methylation and unmethylation are indicated by the horizontal bars
below the vertical lines marking the individual CpG sites. Individ-
ual CpG sites of each PCR clone are indicated as circles in a clone-
numbered row. A closed circle marks a methylated CpG and an
open circle marks an unmethylated CpG. The methylation com-
position of the PCR clones was heterogeneous in similarity with a
broad range of methylated and unmethylated band intensities. One
or two primer-template sequence mismatches produced weak
band intensities. Multiple sequence mismatches in the primer
regions of the hMLH1 CpG islands (normal clone 6 and tumor
clone 4 in case 43) produced none of the methylation and unmethy-
lation bands.
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and/or be potentially associated with the hypermethylation-
dependent LOH-B cases (15, 16). The high-level chromoso-
mal losses stimulate the hypomethylation-dependent pathway
requiring no hypermethylation. The low-grade hypomethy-
lation compensating for the LOH-L cases is thought to atten-
uate the extent of hypermethylation at high risk (Fig. 7). Alter-
natively, the low-level chromosomal losses are likely to coop-
erate with the hypermethylation for the development and
progression of a low-risk gastric carcinoma.
It should be noted that multidirectionally differentiated
mixed cancers such as a sarcomatoid carcinoma (30) and a
glandular-neuroendocrine carcinoma (31) as well as hetero-
geneous tumor sites of a gastric carcinoma commonly have
divergent losses involving different alleles on the same chro-
mosome. Considering that epigenetic changes occur only in
dividing cells (32), the divergent losses bifurcated in mixed
tumors suggest that a genome dosage reduction results in
the gradual and heterogeneous hypomethylation during car-
cinogenesis, which give rise to the expansion of dissimilar
subclones driven by the same chromosomal loss.
Assuming the compensative interactions between the chro-
mosomal losses and the methylation changes maintain a geno-
mic dosage, the extent of irreversible chromosomal losses and
the pattern of reversible methylation are likely to be stable
and are unlikely to progress from the LOH-L cases to the
LOH-H or LOH-B cases. In a previous LOH study using the
same microsatellite markers (8), a lymph node metastasis
and extraserosal invasion were frequent irrespective of the
tumor size in the LOH-H and LOH-B cases. In contrast, in
the LOH-L cases, the rate of a lymph node metastasis and
extraserosal invasion increased linearly with the increased
tumor size. The age of onset and the tumor size in the LOH-L
and LOH-H cases, which were significantly associated with
the early and advanced tumor stage, respectively, were simi-
lar (Table 8). It is likely that the clinical course of a gastric car-
cinoma is determined at the early stage and is dependent on
the stem-line extent of chromosomal losses before tumor cells
appear as a visible mass.
The MSI cases demonstrated frequent hypermethylation
and infrequent hypomethylation (Fig. 3), which is in agree-
ment with a subset of gastric carcinomas positive for MSI
and MINT (15, 33). The MSI cases associated with a good
prognosis contain many cancer-related mutations caused by
hypermethylation silencing the mismatch repair gene. The
accumulation of irreversible gene mutation might be disad-
vantageous over the viable tumor cells due to the lack of a
physiological gene function. Unlike the reversible methyla-
tor phenotype, the irreversible mutator phenotype appears
to lead to a favorable clinical course. 
Fig. 6. Pattern of methylation differences in the CpG island (    )
and non-island CpG (    ) area of the p16 (A) and hMLH1 (B) genes.
The gastric carcinoma was classified as four microsatellite geno-
types. The classification of the microsatellite genotypes is detailed
in the ‘‘Materials and Methods’’ section. The decreased methyla-
tion differences in the LOH-H cases and the increased methyla-
tion differences in the LOH-L, LOH-B, and MSI cases were ob-
served in the methylation gradient region between the CpG islands
and non-island CpG area of the same gene. The increased methy-
lation (M1-4) and decreased methylation (U1-4) differences are
indicated by a difference in methylation grade between the gastric
mucosa and the gastric carcinoma. The bar and error bar repre-
sents the mean and SEM of the methylation grade difference. 
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Fig. 7. Schematic illustration of the CpG methylation status dislodg-
ed dependent on the extent of chromosomal losses. A methyla-
tion gradient between the undermethylated CpG-rich promoter
region (CpG island) and the overmethylated CpG-poor region
(non-island CpG) is prone to both hypo- and hypermethylation.
The high-level (LOH-H) and low-level (LOH-L) chromosomal losses
stimulate the variable hypomethylation in the methylation-gradient
regions via dosage-compensation mechanism. Significant hypo-
methylation in the LOH-H cases demethylate the initial hyperme-
thylation, leading to few hypermethylation. Meanwhile, the LOH-L
cases are under the influence of low-grade hypomethylation and
retain the initial methylation changes.804 S.-J. Hong, Y.-H. Kim, Y.-D. Choi, et al.
The present methylation analysis of the paired normal and
tumor tissues identified an epigenetic heterogeneity in the
CpG islands as well as in the non-island CpGs adjacent to
the cancer-related and -unrelated genes. A complete conver-
sion of the methylation status in the tumor tissues was quite
rare in the CpG sites examined (Fig. 4B). A high tumor cell
contents ≥90% tended to increase both the low- and high-
grade methylation differences (Fig. 4C). The amplification
intensity of the MSP analysis along with the methylated CpG
composition identified by bisulfite sequencing also showed
a wide range of methylation densities in the CpG islands and
non-island CpGs (Fig. 5). Previous bisulfite sequencing analy-
ses on tumor cell lines and pure primary tissues have also
reported a wide range of methylation densities in the CpG
island regions of the Maspin, CAGE, E-cadherin, p16, and
hMLH1 genes (26, 27, 34-36). This indicates that the het-
erogeneous methylation changes in the 5′ -franking regions
were generalized over the tumor tissues.
The hypermethylation status in the CpG islands examined
in this study were extensively examined in previous studies
on gastric carcinomas, and the rates reported in the literature
varied from 10% to as high as 67% for the p16 CpG island
(37, 38) and from 18% to 33% for the hMLH1 CpG island
(33, 39). Moreover, the CpG island hypermethylation was
also observed in 0-67% of the normal gastric mucosa (15,
39). In this study, the incompletely unmethylated CpG island
of the hMLH1 gene (33%) was frequently methylated (48%)
and completely unmethylated CpG islands of the p16 and
RASSF1A genes were slightly methylated (18% and 14%).
The methylation differences between gastric mucosa and
tumor were more prominent in variably methylated non-
island CpGs than relatively unmethylated CpG islands of
the hMLH1 and p16 genes (Fig. 6). The normal lymph nodes
contained an increased methylated density in the CpG islands
of the hMLH1 and Maspin genes and the non-island CpGs
of the RABGEF1 gene compared with the normal gastric
mucosa (Fig. 3). The wide hypermethylation rates might be
caused by the genomic position of the CpG sites examined
and the cell content of the normal and tumor tissues.
The number of PCR cycles is important for an unbiased
amplification of the bisulfite-modified heterogeneous sequences.
This study performed a minimum number of 32 PCR cycles
using a radioisotope for the slightly erroneous PCR products.
The heterogeneous tumor tissues in each case tended to have
a pattern of increased or decreased methylation differences,
but not both differences, in a CpG region that was dependent
on the stem-line extent of chromosomal losses (Fig. 4A). Only
one case (case 28) contained low-level (two) and high-level
(four) chromosomal losses as well as a similar methylation
pattern in the heterogeneous sites. These findings support a
close relationship between the chromosomal loss and the het-
erogeneous methylation differences. The biased MSP condi-
tion is unlikely given to the pattern of methylation differences
measured in the paired normal and tumor tissues.
This multifocal genetic and epigenetic study on gastric
carcinomas can explain the tumor progression process based
on the stem-line chromosomal losses and the compensative
or cooperative reversible epigenetic changes. The extent of
the chromosomal losses is believed to drive the diverse pro-
gression of a gastric carcinoma via a dosage compensative
mechanism that influences the methylation status of the tumor
cells.
REFERENCES
1. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer.
Nat Genet 2003; 33: 238-44.
2. Lasko D, Cavenee W, Nordenskjold M. Loss of constitutional heterozy-
gosity in human cancer. Annu Rev Genet 1991; 25: 281-314.
3. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC,
Nakamura Y, White R. Allelotype of colorectal carcinomas. Science
1989; 244: 207-11.
4. Choi SW, Lee KJ, Bae YA, Min KO, Kwon MS, Kim KM, Rhyu
MG. Genetic classification of colorectal cancer based on chromoso-
mal loss and microsatellite instability predicts survival. Clin Cancer
Res 2002; 8: 2311-22.
5. Nagel S, Borisch B, Thein SL, Oestreicher M, Nothiger F, Birrer S,
Tobler A, Fey MF. Somatic mutations detected by mini- and microsatel-
lite DNA markers reveal clonal intratumor heterogeneity in gastroin-
testinal cancers. Cancer Res 1995; 55: 2866-70.
6. Chung YJ, Choi JR, Park SW, Kim KM, Rhyu MG. Evidence for two
modes of allelic loss: multifocal analysis on both early and advanced
gastric carcinomas. Virchows Arch 2001; 438: 31-8.
7. Kim KM, Kwon MS, Hong SJ, Min KO, Seo EJ, Lee KY, Choi SW,
Rhyu MG. Genetic classification of intestinal-type and diffuse-type
gastric cancers based on chromosomal loss and microsatellite insta-
bility. Virchows Arch 2003; 443: 491-500.
8. Hong SJ, Choi SW, Lee KH, Lee S, Min KO, Rhyu MG. Preopera-
tive genetic diagnosis of gastric carcinoma based on chromosomal
loss and microsatellite instability. Int J Cancer 2005; 113: 249-58.
9. Meller VH. Dosage compensation: making 1X equal 2X. Trends Cell
Biol 2000; 10: 54-9.
10. Muller H. Why polyploid is rarer in animals than in plants. American
Nature 1925; 59: 346-53.
11. Gallardo MH, Bickham JW, Honeycutt RL, Ojeda RA, Kohler N.
Discovery of tetraploidy in a mammal. Nature 1999; 401: 341.
12. Ehrlich M. DNA methylation in cancer: too much, but also too little.
Oncogene 2002; 21: 5400-13.
13. Lin CH, Hsieh SY, Sheen IS, Lee WC, Chen TC, Shyu WC, Liaw
YF. Genome-wide hypomethylation in hepatocellular carcinogene-
sis. Cancer Res 2001; 61: 4238-43.
14. Henikoff S. Heterochromatin function in complex genomes. Biochim
Biophys Acta 2000; 1470: 1-8.
15. Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, Choi C, Juhng SW,
Rashid A, Hamilton SR, Wu TT. Frequent CpG island methylation
in precursor lesions and early gastric adenocarcinomas. Oncogene
2004; 23: 4646-54.Chromosomal Loss and CpG Methylation Change in Gastric Carcinoma 805
16. Ward RL, Cheong K, Ku SL, Meagher A, O’Connor T, Hawkins NJ.
Adverse prognostic effect of methylation in colorectal cancer is reversed
by microsatellite instability. J Clin Oncol 2003; 21: 3729-36.
17. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP.
Comment on ‘‘Chromosomal instability and tumors promoted by
DNA hypomethylation’’ and ‘‘Induction of tumors in mice by genom-
ic hypomethylation’’. Science 2003; 302: 1153.
18. Lauren P. The two histological main types of gastric carcinoma: dif-
fuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol
Scand 1965; 64: 31-49.
19. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG,
Morrow M. AJCC cancer staging maunal. Berlin Heidelberg New
York: Springer Verlag, 2002.
20. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping
of methylated cytosines. Nucleic Acids Res 1994; 22: 2990-7.
21. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz
S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD,
Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional con-
sequences of hMLH1 promoter hypermethylation in colorectal car-
cinoma. Proc Natl Acad Sci USA 1998; 95: 6870-5.
22. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS,
Teo PM, Johnson PJ, Huang DP. High frequency of promoter hyper-
methylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res
2001; 61: 3877-81.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methy-
lation-specific PCR: a novel PCR assay for methylation status of
CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
24. Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi
M, Sugimura T, Tatematsu M, Ushijima T. Frequent hypomethyla-
tion in multiple promoter CpG islands is associated with global hypo-
methylation, but not with frequent promoter hypermethylation. Cancer
Sci 2004; 95: 58-64.
25. Kokkola A, Monni O, Puolakkainen P, Nordling S, Haapiainen R,
Kivilaakso E, Knuutila S. Presence of high-level DNA copy number
gains in gastric carcinoma and severely dysplastic adenomas but not
in moderately dysplastic adenomas. Cancer Genet Cytogenet 1998;
107: 32-6.
26. Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T.
Cell-type-specific repression of the maspin gene is disrupted frequently
by demethylation at the promoter region in gastric intestinal meta-
plasia and cancer cells. Am J Pathol 2003; 163: 1911-9.
27. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, Kim HY, Lee
YS, Kang GH, Jeoung DI. Promoter hypomethylation of a novel can-
cer/testis antigen gene CAGE is correlated with its aberrant expres-
sion and is seen in premalignant stage of gastric carcinoma. Biochem
Biophys Res Commun 2003; 307: 52-63.
28. Martin L, Assem M, Piard F. Are there several types of colorectal
carcinomas? Correlations with genetic data. Eur J Cancer Prev 1999;
8 (Suppl 1): 13-20.
29. Bariol C, Suter C, Cheong K, Ku SL, Meagher A, Hawkins N, Ward
R. The relationship between hypomethylation and CpG island methy-
lation in colorectal neoplasia. Am J Pathol 2003; 162: 1361-71.
30. Kwon MS, Hong SJ, Cho HA, Ahn GH, Lee SS, Lee KY, Rhyu MG.
Extensive and divergent chromosomal losses in squamous and spin-
dle-cell components of esophageal sarcomatoid carcinoma. Virchows
Arch 2003; 443: 635-42.
31. Kim KM, Kim MJ, Cho BK, Choi SW, Rhyu MG. Genetic evidence
for the multi-step progression of mixed glandular-neuroendocrine
gastric carcinomas. Virchows Arch 2002; 440: 85-93.
32. Velicescu M, Weisenberger DJ, Gonzales FA, Tsai YC, Nguyen CT,
Jones PA. Cell division is required for de novo methylation of CpG
islands in bladder cancer cells. Cancer Res 2002; 62: 2378-84.
33. Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K,
Yasui W. DNA methylation of multiple genes in gastric carcinoma:
association with histological type and CpG island methylator phe-
notype. Cancer Sci 2003; 94: 901-5.
34. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathya-
narayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF.
Aberrant methylation of the CDH13 (H-cadherin) promoter region
in colorectal cancers and adenomas. Cancer Res 2002; 62: 3382-6.
35. Song SH, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH,
Bang YJ. Methylation of specific CpG sites in the promoter region
could significantly down-regulate p16(INK4a) expression in gastric
adenocarcinoma. Int J Cancer 2000; 87: 236-40.
36. Kang GH, Lee S, Shim YH, Kim JC, Ro JY. Profile of methylated
CpG sites of hMLH1 promoter in primary gastric carcinoma with
microsatellite instability. Pathol Int 2002; 52: 764-8.
37. Sarbia M, Geddert H, Klump B, Kiel S, Iskender E, Gabbert HE.
Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF
and APC) in adenocarcinomas of the upper gastrointestinal tract.
Int J Cancer 2004; 111: 224-8.
38. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung
SC, Sung JJ, To KF. Detection of gene promoter hypermethylation
in the tumor and serum of patients with gastric carcinoma. Clin Can-
cer Res 2002; 8: 1761-6.
39. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T.
Promoter methylation status of E-cadherin, hMLH1, and p16 genes
in nonneoplastic gastric epithelia. Am J Pathol 2002; 161: 399-403.